Swiss National Bank raised its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 182,500 shares of the medical research company’s stock after purchasing an additional 1,300 shares during the period. Swiss National Bank owned 0.17% of PerkinElmer worth $12,436,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Envestnet Asset Management Inc. grew its holdings in PerkinElmer by 28.1% during the first quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 434 shares during the last quarter. Twin Tree Management LP acquired a new position in PerkinElmer during the first quarter valued at approximately $122,000. Ameritas Investment Partners Inc. acquired a new position in PerkinElmer during the first quarter valued at approximately $152,000. LS Investment Advisors LLC grew its holdings in PerkinElmer by 36.9% during the first quarter. LS Investment Advisors LLC now owns 2,817 shares of the medical research company’s stock valued at $164,000 after purchasing an additional 759 shares during the last quarter. Finally, Harvest Management LLC acquired a new position in PerkinElmer during the first quarter valued at approximately $201,000. Institutional investors own 91.69% of the company’s stock.

In related news, insider Andrew Okun sold 4,358 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $65.00, for a total transaction of $283,270.00. Following the transaction, the insider now directly owns 16,799 shares of the company’s stock, valued at approximately $1,091,935. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by insiders.

Shares of PerkinElmer, Inc. (NYSE PKI) opened at 68.30 on Tuesday. The stock has a 50 day moving average of $65.66 and a 200 day moving average of $62.56. PerkinElmer, Inc. has a 52 week low of $45.35 and a 52 week high of $70.16. The firm has a market cap of $7.53 billion, a P/E ratio of 20.60 and a beta of 0.74.

PerkinElmer (NYSE:PKI) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $547 million for the quarter, compared to analyst estimates of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The firm’s revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 EPS. Equities analysts forecast that PerkinElmer, Inc. will post $2.89 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Investors of record on Friday, October 20th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s payout ratio is presently 8.46%.

Several equities analysts have commented on PKI shares. BidaskClub downgraded PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price target on the stock in a report on Wednesday, July 19th. Piper Jaffray Companies reiterated a “buy” rating and set a $81.00 price target on shares of PerkinElmer in a report on Friday, August 4th. Citigroup Inc. increased their price target on PerkinElmer from $67.00 to $74.00 and gave the company a “buy” rating in a report on Monday, August 7th. Finally, Cantor Fitzgerald reiterated a “hold” rating on shares of PerkinElmer in a report on Sunday, July 16th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $67.00.

COPYRIGHT VIOLATION WARNING: “Swiss National Bank Has $12.44 Million Holdings in PerkinElmer, Inc. (PKI)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/12/swiss-national-bank-has-12-44-million-holdings-in-perkinelmer-inc-pki.html.

PerkinElmer Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Stock Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related stocks with our FREE daily email newsletter.